Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine + Carboplatin as First Line Treatment for Patients Diagnosed With Triple Negative Metastatic Breast Cancer

NCT01201265 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01201265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01201265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine + Carboplatin as First Line Treatment for Patients Diagnosed With Triple Negative Metastatic Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
April 30, 2015
Enrollment
40 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer